Caring Ambassadors Hepatitis C Program Newsletter

www.HepCChallenge.org

August 2009

 

Clinical Trials, Cohort Studies, Pilot Studies

 

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

McHutchison JG, Lawitz EJ, Shiffman ML, et al. N Engl J Med. 2009 Jul 22. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19625712?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Immunological and mutagenic actions of ribavirin monotherapy preceding combination therapy with interferon for patients with chronic hepatitis C. Ogawa K, Hige S, Nakanishi M, et al. Antivir Ther. 2009;14(4):513-22.

http://www.ncbi.nlm.nih.gov/pubmed/19578236?ordinalpos=5&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C. Arase Y, Suzuki F, Suzuki Y, et al. J Med Virol. 2009 Jul 21;81(9):1584-1590. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19623665?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin. Martinot-Peignoux M, Maylin S, Moucari R, et al. Antivir Ther. 2009;14(4):501-11.

http://www.ncbi.nlm.nih.gov/pubmed/19578235?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Morphometric analysis of hepatic steatosis in chronic hepatitis C infection. Zubair A, Jamal S, Mubarik A. Saudi J Gastroenterol. 2009 Jan;15(1):11-4.

http://www.ncbi.nlm.nih.gov/pubmed/19568548?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin. Elefsiniotis IS, Vezali E, Mihas K, Saroglou G. : Intervirology. 2009 Jul 14;52(5):247-251. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Elefsiniotis%20IS%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Hepatic iron, serum ferritin, HFE mutation, and hepatic fibrosis in chronic hepatitis C.

Won JE, Jeong SH, Chung JI, Lee JH, Hwang SH, Kim JW, Lee SH, Kim N, Park YS, Lee DH, Kim H. Intervirology. 2009 Jul 14;52(5):239-246. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Won%20JE%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks. Suzuki F, Akuta N, Suzuki Y, et al. Hepatol Res. 2009 Jul 10. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19619256?ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Symptomatic and pathophysiologic predictors of hepatitis C virus progression in pediatric patients. Henderson WA, Shankar R, Feld JJ, Hadigan CM. Pediatr Infect Dis J. 2009 Jul 10. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19593250?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Sustained responders have better quality of life and productivity compared  with treatment failures long after antiviral therapy for hepatitis C. John-Baptiste AA, Tomlinson G, Hsu PC, et al. Am J Gastroenterol. 2009 Jun 30. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22John-Baptiste%20AA%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Pegylated interferon and ribavirin-induced depression in chronic hepatitis C: role of personality. Castellvi P, Navinés R, Gutierrez F, et al. J Clin Psychiatry. 2009 Jun;70(6):817-28.

http://www.ncbi.nlm.nih.gov/pubmed/19573480?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Serum HCV RNA levels and HCV genotype do not affect insulin resistance in non-diabetic patients with chronic hepatitis C: a multicentre study. Tsochatzis E, Manolakopoulos S, Papatheodoridis GV, et al. Aliment Pharmacol Ther. 2009 Jul 9. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Tsochatzis%20E%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment. Durante-Mangoni E, Zampino R, Portella G, Adinolfi LE, Utili R, Ruggiero G. Clin Infect Dis. 2009 Aug 15;49(4):498-506.

http://www.ncbi.nlm.nih.gov/pubmed/19591593?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Basic and Applied Science, Pre-Clinical Studies

 

The role of nucleoside transporters in the erythrocyte disposition and oral absorption of ribavirin in the wild-type and equilibrative nucleoside transporter 1 (-/-) mice. Endres CJ, Moss AM, Govindarajan R, Choi DS, Unadkat JD. J Pharmacol Exp Ther. 2009 Jul 14. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19602549?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

 

 

 

Non-structural 5A protein of hepatitis C virus induces a range of liver pathology in transgenic mice. Wang AG, Lee DS, Moon HB, et al. J Pathol. 2009 Jun 18. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19621337?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Predictive value of suppressor of cytokine signal 3 (SOCS3) in the outcome of interferon therapy in chronic hepatitis C. Miyaaki H, Ichikawa T, Nakao K, et al. Hepatol Res. 2009 Jul 13. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19624774?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

FOXP3+ expression in hepatitis C virus specific CD4+ T cells during acute hepatitis C.

Heeg MH, Ulsenheimer A, Grüner NH, et al. Gastroenterology. 2009 Jul 10. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Heeg%20MH%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Specific activation of 2'-5'oligoadenylate synthetase gene promoter by hepatitis C virus-core protein: a potential for developing hepatitis C virus targeting gene therapy. Wang Y, Mao SS, He QQ, Zi Y, Wen JF, Feng DY.

http://www.ncbi.nlm.nih.gov/pubmed/19575500?ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

HIV/HCV Coinfection

 

Analysis of the efficacy of treatment with peginterferon alpha-2a and ribavirin in patients coinfected with hepatitis B virus and hepatitis C virus. Yu JW, Sun LJ, Zhao YH, Kang P, Gao J, Li SC. Liver Int. 2009 Jul 7. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Yu%20JW%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells. Eyre NS, Phillips RJ, Bowden S, Yip E, Dewar B, Locarnini SA, Beard MR. J Hepatol. 2009 Jun 3. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19596477?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Prevalence of cryoglobulinaemia in hepatitis C virus- and hepatitis C virus/human immunodeficiency virus-infected individuals: implications for renal function. Lapinski TW, Parfieniuk A, Rogalska-Plonska M, Czajkowska J, Flisiak R. Liver Int. 2009 Jul 7. [Epub ahead of print]

 

Sustained virological response to interferon plus ribavirin reduces liver-related compli-cations and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Berenguer J, Alvarez-Pellicer J, Martín PM, et al. Hepatology. 2009 Jul 2. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19575364?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

Predictability of sustained virological response to pegylated interferon alpha-2b Plus ribavirin therapy by week-8 viral response in HIV-positive patients with chronic hepatitis C virus infection.  Angeli E, Mainini A, Cargnel A, et al. Curr HIV Res. 2009 Jul;7(4):447-55.

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Angeli%20E%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis. d'Arminio Monforte A, Cozzi-Lepri A, Castagna A, et al. Clin Infect Dis. 2009 Aug 15;49(4):612-22.

http://www.ncbi.nlm.nih.gov/pubmed/19591597?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Sustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfection. Schulze Zur Wiesch J, Pieper D, Stahmer I, et al. Clin Infect Dis. 2009 Aug 1;49(3):466-72.

http://www.ncbi.nlm.nih.gov/pubmed/19580412?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients. Morsica G, Bagaglio S, Cicconi P, et al. J Acquir Immune Defic Syndr. 2009 Aug;51(5):574-581.

http://www.ncbi.nlm.nih.gov/pubmed/19590432?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Epidemiology, Diagnostics, and Miscellaneous Works

 

Safe using messages may not be enough to promote behaviour change amongst injecting drug users who are ambivalent or indifferent towards death. Miller PG. Harm Reduct J. 2009 Jul 25;6(1):18. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19630988?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Visualizing hepatitis C virus infections in human liver by two-photon microscopy.

Liang Y, Shilagard T, Xiao SY, et al. Gastroenterology. 2009 Jul 23. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19632233?ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Evaluation of the Abbott IUO RealTime HCV Assay and comparison to the Roche TaqMan HCV Analyte Specific Reagent. Pyne MT, Konnick EQ, Phansalkar A, Hillyard DR. J Clin Microbiol. 2009 Jul 22. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/19625475?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Non-conventional transmission of hepatitis C: a true possibility ignored. Hyder Q, Burhan-ul-Haq M, Rashid R, Qazi S, Mehmood S, Hadi SF. J Pak Med Assoc. 2009 Jul;59(7):430-3.

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Hyder%20Q%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

New and experimental therapies for HCV. Pereira AA, Jacobson IM. Nat Rev Gastroenterol Hepatol. 2009 Jul;6(7):403-11.

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Pereira%20AA%22%5BAuthor%5D&itool=Email.EmailReport.Pubmed_ReportSelector.Pubmed_RVAbstract

 

Seroepidemiology of hepatitis C antibodies among dentists and their self-reported use of infection control measures. Ashkenazi M, Fisher N, Levin L, Littner MM. Community Dent Health. 2009 Jun;26(2):99-103.

http://www.ncbi.nlm.nih.gov/pubmed/19626741?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Viral hepatitis in a homeless shelter in Hawai'i. Boyce DE, Tice AD, Ona FV, Akinaka KT, Lusk H. Hawaii Med J. 2009 Jun;68(5):113-5.

http://www.ncbi.nlm.nih.gov/pubmed/19583106?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

 

Living with hepatitis C and treatment: the personal experiences of patients. Sgorbini M, O'Brien L, Jackson D. J Clin Nurs. 2009 Aug;18(16):2282-91.

http://www.ncbi.nlm.nih.gov/pubmed/19583661?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum